Derivatives of 5-phenyl- or 5-heteroarylathiazol-2-carboxylic amide useful for the treatment of inter alia cystic fibrosis
US10392378B2 · kind B2 · utility
6Cited by
11References
8Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 23, 2015 |
| Grant date | Aug 27, 2019 |
| Priority date | — |
| Expiry date | Dec 23, 2035 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N33/5044
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present disclosure is based, in part, on the discovery that disclosed compounds such as those having Formula (IIIa), (III), or (IV) can increase cystic fibrosis transmembrane conductance regulator (CFTR) activity as measured in human bronchial epithelial (hBE) cells.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.